Abstract W P57: Thrombolytic Therapy in Patients With Mild Stroke: An Observational Study
Objective: Mild stroke has traditionally been excluded from thrombolytic treatment trials and only few series have reported outcomes after IV rtPA in this group. The objectives of this study are to determine the proportion of mild stroke patients treated with IV rtPA and evaluate complications and short-term outcomes in this population.
Methods: We analyzed patients in the Get With The Guidelines-Stroke registry that arrived within 4.5 hours from symptom onset with a mild ischemic stroke defined as a baseline NIHSS ≤5 who received IV rtPA between May 2010 and October 2012. The following outcomes and complications were analyzed: in-hospital mortality, home discharge, independent ambulation, length of stay (LOS), in-hospital death, and symptomatic intracranial hemorrhage (sICH) <36 h. Multivariable analysis was performed for predictors of outcomes and complications.
Results: Of 147,917 patients who arrived <4.5 hours, 39,821 were treated with IV rtPA, of whom 8,243 (20.7%) had an NIHSS ≤5. We analyzed 5,910 treated patients with NIHSS ≤5 and complete data. The mean baseline NIHSS was 3.5 (median 4); 98.2% arrived within 3 hours and 78.6% were treated within 3 hours. Outcomes and predictors of worse outcome are described in the table. There was no difference in short-term outcomes amongst those treated at 0-3 vs. 3-4.5 hours.
Conclusions: A sizeable minority of ischemic stroke patients treated with IV rtPA have a NIHSS ≤5. sICH occurred at a low rate of 1.8% and about 30% of these patients were unable to return home and could not ambulate independently. Longer-term outcomes are needed to define predictors of poor outcome in this population and which patients may benefit most from treatment.
Author Disclosures: J.G. Romano: Research Grant; Significant; PI MaRISS Study, GenentechI MaRISS Study, Genentech. E.E. Smith: None. L. Liang: None. H. Gardener: Research Grant; Significant; Statistician, MaRISS, Genentech. S. Camp: None. L. Shuey: None. I. Campo-Bustillo: Research Grant; Significant; Project Manager, MaRISS, Genentech. P. Khatri: Research Grant; Significant; PRISMS Trial, PI, Genentech; IMS III Trial, SPOTRIAS (Comm Core PI, CLEAR FDR EC, STOP IT Co-I), GCNK Epi Co-I, NIH;. Other Research Support; Significant; PRISMS Trial, PI, Genentech; Penumbra-THERAPY Trial PI. Honoraria; Modest; Lehigh Valley Symposium; Alexian Grand Rounds; AAN Lectures. Other; Modest; Taylor and Francis-Stroke Ctr Handbook book. D.L. Bhatt: Consultant/Advisory Board; Significant; Chair: American Heart Association Get With The Guidelines Steering Committee; Duke Clinical Research Institute (clinical trial steering committees). G.C. Fonarow: Other; Significant; Dr. Fonarow is an employee of the University of California, which holds a patent on retriever devices for stroke. R.L. Sacco: None. L.H. Schwamm: Consultant/Advisory Board; Modest; Joint Commission; MA Dept of Public Health. Other; Modest; AHA Get With the Guidelines (unpaid); Coverdell Registry Advisor (unpaid); MGH provides telehealth services under contract to hospitals in northern new england. Employment; Significant; Director, MassGeneral TeleHealth.
- © 2014 by American Heart Association, Inc.